HACL1 and breast cancer: For TGFB2-dependent biomarkers, elevated TGFB2 mRNA expression is a prognostic biomarker associated with breast cancer patients that is correlated with improved OS outcomes at high expression levels of GDAP1, TBL1XR1, RNFT1, HACL1, SLC27A2, NLE1, and TXNDC16.